Skip to main content
SpringerLink
Log in

Generation of lymphokine-activated killer cells in human ovarian carcinoma ascitic fluid: Identification of transforming growth factor-β as a suppressive factor

  • Original articles
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Summary

The effect of cell-free ascitic fluid from patients with epithelial ovarian carcinoma on the generation of lymphokine-activated killer cells (LAK) was compared to the activity generated in control medium containing 10% fetal bovine serum, using Daudi target cells. Samples of ascitic fluid from nine different patients tested inhibited LAK generation. Suppressive activity was evident as early as 24 h of incubation in the presence of ascitic fluid and increasing suppression developed with prolonged exposure. Suppression was concentration-dependent, present at 10%–20% and increasing with concentrations up to 80%. The suppressive effect of ascitic fluid was only partially reversed on increasing the concentration of interleukin-2 (IL-2) from 10 units to 1000 units/ml. Activated LAK appeared to maintain the majority of their activity on further culture in ascitic fluid in the presence of IL-2 but further enhancement of lytic activity was prevented. Fractionation of a suppressive sample by HPLC, using 0.1 M KCl/acetic acid buffer pH 2.6, revealed that the dominant peak of suppressive activity eluted at 25 kDa; with pH 7.0 TRIS-buffered saline, most of the activity was lost on the column. Antibody neutralization studies of the 25-kDa suppressive peak as well as on whole ascitic fluid have revealed that transforming growth factor β (TGFβ) is the major suppressive factor present in ascitic fluid. Factors that suppress LAK generation in vitro were present in all samples tested. The effect on the lytic activity of activated LAK cells was minimal. This suggests that, in the clinical setting, the greatest impact would be achieved by activating LAK cells ex vivo and subsequently transferring them to the peritoneal cavity in the presence of IL-2 rather than by attempting to generate them in situ by injecting IL-2 into the peritoneal cavity. However, reversal of TGFβ-mediated suppression in situ may be necessary to allow local proliferation of LAK cells to achieve an effective killer-totarget ratio.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Anzano MA, Roberts AB, Smith JM, Sporn MB, DeLaco JE (1983) Sarcoma growth factor from conditioned medium of virally transformed cells is composed of both type a and type b transforming growth factors. Proc Natl Acad Sci USA 80: 6264

    Google Scholar 

  2. Anzano MA, Roberts AB, DeLaco JE, Wakefield LM, Assoian RK, Roche NS, Smith JM, Lazarus JE, Sporn MB (1985) Increased secretion of type beta transforming growth factor accompanies viral transformation of cells. Mol Cell Biol 5: 242

    Google Scholar 

  3. Badger AM, Oh SK, Moolten FR (1981) Differential effects of an immunosuppressive fraction from ascites fluid of patients with ovarian cancer on spontaneous and antibody-dependent cytotoxicity. Cancer Res 41: 1133

    Google Scholar 

  4. Cianciolo GJ, Copeland TD, Oroszlan S, Snyderman R (1985) Inhibition of lymphocyte proliferation by a synthetic peptide homologous to retroviral envelope proteins. Science 230: 453

    Google Scholar 

  5. Cianciolo GJ, Snyderman R (1986) Effects of tumor growth on host defenses. Cancer Metastasis Rev 5: 15

    Google Scholar 

  6. Clark J, Longo DL (1989) Lymphokine-activated killer lymphocytes: National Cancer Institute clinical trials. Adoptive cellular immunotherapy of cancer. Dekker, New York, p 37

    Google Scholar 

  7. Clark DA, Phillips RA, Miller RG (1977) Characterization of the cells that suppress the cytotoxic activity of T lymphocytes: II. Physical properties, specificity, and developmental kinetics of the inhibitory splenic non-T cell population. Cell Immunol 34: 25

    Google Scholar 

  8. Djeu JY, Kavanagh JJ, Sinkovics JG, Cavanagh D, Blanchard DK (1989) Activation of killer cells by interleukin-2 in ascitic fluid and pleural effusions of advanced cancer patients. Proc Assoc Cancer 30: 369

    Google Scholar 

  9. Fumita Y, Tanaka F, Saji F, Nakamuro K (1984) Immunosuppressive factors in ascites fluids from ovarian cancer patients. Am J Reprod Immunol Microbiol 6: 175

    Google Scholar 

  10. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA (1982) Lymphokine-activated killer cell phenomenon: lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 155: 1823

    Google Scholar 

  11. Grimm EA, Crump WL, Durett A, Hester JP, Lagoo-Deenadalayan S, Owen-Schaub LB (1988) TGF-beta inhibits the in vitro induction of lymphokine-activated killing activity. Cancer Immunol Immunother 27: 53

    Google Scholar 

  12. Guillou PJ, Sedman PC, Ramsden CW (1989) Inhibition of lymphokine-activated killer cell generation by cultured tumor cell lines in vitro. Cancer Immunol Immunother 28: 43

    Google Scholar 

  13. Harris DT, Cianciolo GJ, Snyderman R, Argov S, Koren HS (1987) Inhibition of human natural killer cell activity by a synthetic peptide homologous to a conserved region in the retroviral protein p15E. J Immunol 138: 889

    Google Scholar 

  14. Hess AD, Gall SA, Dawson JR (1979) Inhibition of in vitro lymphocyte function by cystic and ascitic fluids from ovarian cancer patients. Cancer Res 39: 2381

    Google Scholar 

  15. Hess AD, Gall SA, Dawson JR (1980) Partial purification and characterization of a lymphocyte-inhibitory factors(s) in ascitic fluids from ovarian cancer patients. Cancer Res 40: 1842

    Google Scholar 

  16. Ibayashi Y, Hoon DSB, Golub SH (1987) The regulatory effect of adherent cells on lymphokine activated killer cells. Cell Immunol 110: 365

    Google Scholar 

  17. Itoh K, Pellis NR, Balch CM (1989) Monocyte-dependent, serumborne suppressor of induction of lymphokine-activated killer cells in lymphocytes from melanoma patients. Cancer Immunol Immunother 29: 57

    Google Scholar 

  18. Lafreniere R, Rosenberg SA (1985) Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2. Cancer Res 45: 3735

    Google Scholar 

  19. Leung KH (1989) Inhibition of human NK cell and LAK cell cytotoxicity and differentiation by PGE2. Cell Immunol 123: 384

    Google Scholar 

  20. Lichtenstein AK, Berek J, Zighelboim J (1985) Natural killer inhibitory substance produced by the peritoneal cells of patients with ovarian cancer. J Natl Cancer Inst 74: 349

    Google Scholar 

  21. Loeffler D, Heppner G (1989) Influence of tumor microenvironmental factors on NK and LAK cells. Proc Am Assoc Cancer Res 30: 365

    Google Scholar 

  22. Lotze MT, Grimm EA, Mazumder A, Strausser JL, Rosenberg SA (1981) Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res 41: 4420

    Google Scholar 

  23. Mazumder A, Rosenberg SA (1984) Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2. J Exp Med 159: 495

    Google Scholar 

  24. Mule JJ, Schwarz SL, Roberts AB, Sporn MB, Rosenberg SA (1988) Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells. Cancer Immunol Immunother 26: 95

    Google Scholar 

  25. Oh SK, Moolten FL (1981) Purification and characterization of an immunosuppressive factor from ovarian cancer ascites fluid. Eur J Immunol 11: 780

    Google Scholar 

  26. Owen-Schaub LB, Grimm EA (1989) Lymphokine-activated killer lymphocytes: evidence for regulation of induction and function by multiple cytokines. Adoptive cellular immunotherapy of cancer. Dekker, New York, p 19

    Google Scholar 

  27. Owen-Schaub LB, Gutterman JU, Grimm EA (1988) Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor-alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity. Cancer Res 48: 788

    Google Scholar 

  28. Pross HF, Baines MG, Rubin P, Shragge P, Patterson MS (1981) Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells: IX. The quantitation of natural killer cell activity. J Clin Immunol 1: 51

    Google Scholar 

  29. Ramsdell FJ, Shau H, Golub SH (1988) Role of proliferation in LAK cell development. Cancer Immunol Immunother 26: 139

    Google Scholar 

  30. Ratner S, Heppner GH (1988) Motility and tumoricidal activity of interleukin-2-stimulated lymphocytes. Cancer Res 48: 3374

    Google Scholar 

  31. Riley LB, Pellis NR, Itoh SP (1989) Cancer patients have two distinct inhibitors of LAK induction. Proc Am Assoc Cancer Res 30: 366

    Google Scholar 

  32. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C, Reichert CM (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with metastatic cancer. N Engl J Med 313: 1485

    Google Scholar 

  33. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White MS (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin 2 or high dose interleukin 2 alone. N Engl J Med 316: 889

    Google Scholar 

  34. Sawada M, Okudaira Y, Matsui Y, Shimizu Y (1983) Immunosuppressive acidic protein in patients with ovarian cancer. Cancer 52: 2081

    Google Scholar 

  35. Shau H, Kim A (1988) Suppression of lymphokine-activated killer induction by neutrophils. J Immunol 141: 4395

    Google Scholar 

  36. Sone S, Yanagawa H, Nii A (1989) Lymphokine (IL-2)-activated killer (LAK) induction and its regulation in malignant pleural effusion of lung cancer patients. Proc Am Assoc Cancer Res 30: 373

    Google Scholar 

  37. Steis R, Bookman M, Clark J (1987) Intra-peritoneal lymphokine activated killer (LAK) cell and interleukin-2 (IL-2) therapy for peritoneal carcinomatosis: toxicity, efficacy, and laboratory results. Proc Soc Clin Oncol 6: 250

    Google Scholar 

  38. Stewart J, Belinson J, Grant B (1988) Phase I evaluation of intraperitoneal (IP) interleukin-2 (IL-2) and lymphokine activated killer cells (LAK) in patients with ovarian cancer. Proc Am Soc Clin Oncol 7: 162

    Google Scholar 

  39. Tamura K, Shibata Y, Matsuda Y, Ishida N (1981) Isolation and characterization of an immunosuppressive acidic protein from ascitic fluids of cancer patients. Cancer Res 41: 3244

    Google Scholar 

  40. Taylor DD, Taylor CG, Pelton JJ, Weese JL (1989) Tumor modulation of rIL-2-activated killer (LAK) cells. Abstracts of the Society for Biological Therapy Annual Meeting, Williamsburg, Va., Nov 16–19; p 15

  41. Wrann M, Bodmer S, de Martin R (1987) T cell suppressor factor from human glioblastoma cells is a 12.5 kd protein closely related to transforming growth factor-beta. EMBO J 6: 1633

    Google Scholar 

  42. Xiao J, Brahmi Z (1989) Target cell-directed inactivation and IL-2-dependent reactivation of LAK cells. Cell Immunol 122: 295

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ontario Cancer Treatment and Research Foundation — Hamilton Regional Cancer Centre, and Department of Medicine, McMaster University, Room 4H13, 1200 Main Street West, L8N 3Z5, Hamilton, Ontario, Canada

    Hal Hirte & David A. Clark

Authors
  1. Hal Hirte
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David A. Clark
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Supported by a grant from the National Cancer Institute of Canada D.A.C. is a recipient of a Scientist Award from the Medical Research Council (Canada)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hirte, H., Clark, D.A. Generation of lymphokine-activated killer cells in human ovarian carcinoma ascitic fluid: Identification of transforming growth factor-β as a suppressive factor. Cancer Immunol Immunother 32, 296–302 (1991). https://doi.org/10.1007/BF01789047

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01789047

Keywords

Search

Navigation